0 Recensioner
United States· I lager· Ny
GLP2 TRZ - 30mg
$209.00 (USD)
Three Receptors, One Molecule: The Science of Triple Agonism
Retatrutide represents the next generation of incretin-based research compounds. Unlike dual-agonists such as Tirzepatide, it targets three key receptors simultaneously: GLP-1, GIP, and Glucagon. This triple-agonist mechanism has been extensively documented in peer-reviewed literature for its interaction with metabolic signaling pathways and receptor cross-talk.
Activates GLP-1, GIP, and Glucagon receptors simultaneously
First compound designed with this triple-agonist mechanism
Extended half-life suitable for weekly research protocols
Well-documented in peer-reviewed scientific journals
Stable compound suitable for in-vitro research protocols
Tycka om
Kommentar
Dela med sig
